Brind.

FDA cleared the IND application for AXN-2510, a lead asset developed by Instil Bio and ImmuneOnco.

1 report, 0 independent Updated Jul 2

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

FDA

Keep exploring

The entities involved

FDA
- FDA accepts a BLA for biosimilar review and extends its review process to Health Canada.15:34
- Dario Amodei warns government leaders about AI risks and calls for strict guardrails on AI development.13:44

Coverage

Newest first; wire copies grouped

Jul 2Unknown outlet